## Clinical Context This patient has **cirrhotic hepatitis C (genotype 1b)** with portal hypertension and signs of decompensation (ascites, spider angiomas). Modern hepatitis C treatment has shifted entirely to **direct-acting antivirals (DAAs)**, which offer cure rates >95% regardless of genotype or cirrhosis stage. ## Rationale for DAA Selection in Cirrhotic HCV **Key Point:** In **cirrhotic HCV patients without prior decompensation**, the preferred regimen is **Sofosbuvir + Velpatasvir** — a **pangenotypic, fixed-dose combination** with excellent efficacy, tolerability, and no need for ribavirin or interferon. ### Why Sofosbuvir + Velpatasvir? 1. **Pangenotypic coverage**: Effective for all HCV genotypes (1–6), including genotype 1b 2. **Ribavirin-sparing**: No need for ribavirin in compensated cirrhosis, reducing side effects 3. **Interferon-free**: Avoids peginterferon toxicity (cytopenia, depression, flu-like illness) 4. **Fixed-dose combination**: Improves adherence 5. **SVR12 rates**: >98% in cirrhotic patients 6. **Duration**: 12 weeks (shorter than older regimens) 7. **Renal safety**: Safe even in renal impairment (unlike sofosbuvir monotherapy in eGFR <30) ## Comparative DAA Regimens for Cirrhotic HCV | Regimen | Genotypes | Cirrhosis | Ribavirin | Duration | SVR12 | Notes | |---------|-----------|-----------|-----------|----------|-------|-------| | **Sofosbuvir + Velpatasvir** | 1–6 (pangenotypic) | **Compensated** | No | 12 weeks | >98% | **First-line** | | Ledipasvir + Sofosbuvir | 1, 4, 5, 6 | Compensated | No | 12 weeks | >98% | Genotype 1b-specific; older | | Sofosbuvir + Daclatasvir ± RBV | 1–6 | Compensated/Decompensated | Optional | 12 weeks | >98% | For decompensated cirrhosis | | Peginterferon-α + Ribavirin | 1b | Cirrhosis | Yes | 48 weeks | 40–50% | **Obsolete**; poor outcomes in cirrhosis | ## Why Each Alternative is Suboptimal **High-Yield:** The **2023 AASLD/IDSA HCV Guidance** recommends **Sofosbuvir + Velpatasvir** as the **preferred regimen for all patients with cirrhosis**, regardless of genotype or prior treatment. ```mermaid flowchart TD A[Cirrhotic HCV patient]:::outcome --> B{Decompensated?}:::decision B -->|No| C[Sofosbuvir + Velpatasvir 12 weeks]:::action B -->|Yes| D[Sofosbuvir + Daclatasvir ± Ribavirin]:::action C --> E[SVR12 >98%]:::outcome D --> F[SVR12 >95%]:::outcome ``` **Clinical Pearl:** Ledipasvir + Sofosbuvir is **genotype-specific** (covers 1, 4, 5, 6 but not 2, 3) and is now considered **second-line** in favour of the pangenotypic Sofosbuvir + Velpatasvir. **Warning:** Peginterferon + Ribavirin is **historically important but now obsolete** in the DAA era. It has poor SVR rates in cirrhosis (~40–50%), significant toxicity, and is no longer recommended by any major guideline. [cite:Harrison 21e Ch 304; AASLD/IDSA HCV Guidance 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.